Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts– Hagens Berman

SAN FRANCISCO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing headwinds on multiple fronts, including disappointing sales figures, ongoing legal challenges, and analyst downgrades. TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230, citing increased competition and lower revenue estimates for EYLEA®, a key product. The firm pointed to preannounced January figures for the drug's sales.   This downgrade compounds existing woes. Regeneron i ...